Supplementation Trial of KOKO Plus Among HIV Exposed Children in Accra

NCT ID: NCT04995874

Last Updated: 2021-11-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

649 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-06

Study Completion Date

2022-06-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall aim of the research is to conduct a randomised controlled trial of KOKOPlus in young HIV exposed children attending HIV clinics in Accra, Ghana to test the effectiveness of KOKOPlus over a period of 6 months to improve nutritional status and child development in HIV exposed children 6-18 months of age in Accra

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The specific objectives are to accomplish the following

1. To test the effectiveness of KOKOPlus to improve the nutritional status of HIV exposed infants aged 6-18 months.
2. To measure and compare nutritional status in intervention and control arms by monitoring growth in terms of height and weight over the period of 6 months
3. To measure and compare micronutrient status of intervention and control arms by comparing baseline midline and endline measurements of hemoglobin levels.
4. To measure and compare morbidity rates of intervention and control arms.
5. To measure and compare rates of achievement of child development goals between intervention and control arms using a standardized tool, the Caregiver Reported Early Development Instrument (CREDI).
6. To understand and record experiences relating to the use of KOKOPlus of mothers/caregivers in the intervention arm through focus group discussion

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections Nutrition Poor Child Development

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

HIV-Exposed Nutrient Status KOKOPlus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

KOKOPlus protein and micronutrient powder , a complementary food supplement containing soya powder, sugar and oil along with the essential amino acid lysine and a micronutrient mix was formulated. Two weeks' supply of KOKOPlus sachets will be given to intervention arm participants every fortnight for 6 months to be mixed into any cereal, soup, stew, or other food given to the children.

Group Type EXPERIMENTAL

KOKOPlus protein and micronutrient powder

Intervention Type DIETARY_SUPPLEMENT

KokoPlus, a complementary food supplement was formulated by using linear programming methodology to improve the protein quality as well as the micronutrient and macronutrient content of commonly consumed traditional complementary (baby) foods in Ghana . It contains soya powder, sugar and oil along with the essential amino acid lysine and a micronutrient mix. It complies with WHO's complementary feeding guidelines, FAO/WHO recommended micronutrient intake (RNI) and the WHO's guidelines for protein and essential amino acid intake for children in the age group of 6 to 24 months. A daily supply of KokoPlus achieves 30% of the total recommended energy, 60% of total protein and 40% of total fat requirements from complementary foods. It also meets 35-55% of minimum intake of essential amino acids and 50-150% RNI based on the total daily requirements.

Control

This arm will receive no supplement and no placebo for the duration of the study.,

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

KOKOPlus protein and micronutrient powder

KokoPlus, a complementary food supplement was formulated by using linear programming methodology to improve the protein quality as well as the micronutrient and macronutrient content of commonly consumed traditional complementary (baby) foods in Ghana . It contains soya powder, sugar and oil along with the essential amino acid lysine and a micronutrient mix. It complies with WHO's complementary feeding guidelines, FAO/WHO recommended micronutrient intake (RNI) and the WHO's guidelines for protein and essential amino acid intake for children in the age group of 6 to 24 months. A daily supply of KokoPlus achieves 30% of the total recommended energy, 60% of total protein and 40% of total fat requirements from complementary foods. It also meets 35-55% of minimum intake of essential amino acids and 50-150% RNI based on the total daily requirements.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Mother-infant dyads; HIV positive mothers and children between 6 and 12 months of age attending antiretroviral (ART) Clinics and child HIV Clinics.

Exclusion Criteria

* Mothers who decline to participate in the study

Children with severe acute malnutrition (mid-upper arm circumference \<115 mm or a weight-for-height/length \<-3 Z-scores of the WHO growth standards).

Children on hospital admission

Children with diagnosed or apparent congenital conditions such as encephalitis, cleft palate, hole in heart, which negatively affect the child's ability to eat and/or growth.
Minimum Eligible Age

6 Months

Maximum Eligible Age

18 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

International Food Policy Research Institute

OTHER

Sponsor Role collaborator

Noguchi Memorial Institute for Medical Research

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gloria K Folson

Role: PRINCIPAL_INVESTIGATOR

Noguchi Memorial Institute for Medical Research

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

37 Military Hospital

Accra, Greater Accra Region, Ghana

Site Status RECRUITING

Greater Accra Regional Hospital

Accra, Greater Accra Region, Ghana

Site Status RECRUITING

Korle-bu Teaching Hospital

Accra, Greater Accra Region, Ghana

Site Status RECRUITING

Princess Marie Louise Children's Hospital

Accra, Greater Accra Region, Ghana

Site Status RECRUITING

Ashaiman Polyclinic

Ashaiman, Greater Accra Region, Ghana

Site Status RECRUITING

Tema General Hospital

Tema, Greater Accra Region, Ghana

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Ghana

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gloria K Folson

Role: CONTACT

Phone: +233550006053

Email: [email protected]

Grace S Tokor

Role: CONTACT

Phone: +233243009116

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Philip Nyinaku

Role: primary

Salomey Frimpong

Role: primary

Joycelyn Assiment Dame

Role: primary

Margaret Niezer

Role: primary

Adwoa Amoako

Role: primary

Richard Anthony

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021X018.NMI

Identifier Type: -

Identifier Source: org_study_id